Psychiatry - November 2008 - (Page 52)

Journal Watch et al. Clin Interv Aging. 2008;3(2):211–225. Review. Synopsis: To examine differences among the cholinesterase inhibitors donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease, authors conducted a review of the literature. They found no statistically significant differences among drugs with regard to cognition, but found the relative risk of global response better with donepezil and rivastigmine than with galantamine, behavior was better with donepezil compared to galantamine, and incidence of adverse events was generally lowest for donepezil and highest for rivastigmine. PMID: 18686744 Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. Ballard C, Sauter M, Scheltens P, et al. Curr Med Res Opin. 2008 Sep;24(9):2561–2574. Epub 2008 Jul 31. Synopsis: To evaluate the efficacy, safety and tolerability of rivastigmine capsules in patients diagnosed with probable vascular dementia, researchers randomized 710 vascular dementia patients (50–85 years of age) to rivastigmine capsules (3–12mg/day) or placebo and measured global and cognitive performances, activities of daily living, neuropsychiatric symptoms, and adverse events. They did not find that rivastigmine provided consistent efficacy in probable vascular dementia, and apparent efficacy on cognitive outcomes was derived from effects in older patients likely to have concomitant Alzheimer pathology. PMID: 18674411 a quick look at the noteworthy articles in psychiatry research NOVEMBER 2008 by Laura G. Alexander CHOLINESTERASE INHIBITORS AND TREATMENT OF ALZHEIMER’S Preventing Alzheimer’s disease: separating fact from fiction. Sano M, Grossman H, Van Dyk K. CNS Drugs. 2008;22(11):887–902. Synopsis: In this literature review, authors discuss new and existing treatments for Alzheimer’s disease, including cholinesterase inhibitors, an NMDA receptor antagonist, antioxidants, NSAIDs, hormone replacement, nutritional supplements and nonpharmacological interventions, plus immunotherapy and secretase modulation. PMID: 18840031 Transdermal delivery of treatment for Alzheimer’s 52 Psychiatry 2008 [ N O V E M B E R ] disease: development, clinical performance and future prospects. Chan AL, Chien YW, Jin Lin S. Drugs Aging. 2008;25(9):761–775. Synopsis: Authors focus on cholinesterase inhibitors in their discussion of the technical principles underlying the development of transdermal drug delivery systems, prospects for future development, and clinical performance of transdermal patches. PMID: 18729547 Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: a systematic review and metaanalysis. Hansen RA, Gartlehner G, Webb AP, 52

Table of Contents Feed for the Digital Edition of Psychiatry - November 2008

Psychiatry - November 2008 Editor's Message Editorial Advisory Board Contents PsychRx Letters to the Editor Measuring Adverse Events in Psychiatry Nonsuicidal Self Injury in Adolescents Relative Tolerability of Alzheimer's Disease Treatments Biracial Identity Development and Recommendations in Therapy Depression and Cardiovascular Disease: Just an Urban Legend? Three Risk Management Basics Journal Watch Classified Advertising Information for Authors

Psychiatry - November 2008

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.